Does Empiric Therapy for Atypical Pathogens Improve Outcomes for Patients with CAP? - 09/02/13
, Thomas J. Marrie, MD c
Corresponding author. 75 Arch Street, Suite 506, Akron, OH 44304.Résumé |
The present controversy regarding the need to cover atypical pathogens in the empiric therapy of community-acquired pneumonia is related to several issues, including the relevance of terminology, imprecise diagnostic methods, and perceived contradictory results of published evidence. Studies evaluating the time to clinical recovery and the use of earlier endpoints for evaluation suggest that appropriate therapy provides a benefit if an atypical pathogen is a pathogen. Because recent surveillance studies suggest these pathogens are common and until there is the availability of accurate, cost-effective, and easily interpreted laboratory tests to provide the etiologic diagnosis at the time of point of care, empiric therapy of atypical pathogens is supported.
Le texte complet de cet article est disponible en PDF.Keywords : Community-acquired pneumonia, Atypical, Mycoplasma, Chlamydophila, Legionella, Treatment, Empiric
Plan
Vol 27 - N° 1
P. 99-114 - mars 2013 Retour au numéro
Article précédent
- What Is the Relevance of Antimicrobial Resistance on the Outcome of Community-Acquired Pneumonia Caused by Streptococcus pneumoniae? (Should Macrolide Monotherapy Be Used for Mild Pneumonia?)
- Donald E. Low
- Does Empirical Therapy with a Fluoroquinolone or the Combination of a β-Lactam Plus a Macrolide Result in Better Outcomes for Patients Admitted to the General Ward?
- Jörg Ruhe, Donna Mildvan
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?